Aerovate Therapeutics Inc
NASDAQ:AVTE

Watchlist Manager
Aerovate Therapeutics Inc Logo
Aerovate Therapeutics Inc
NASDAQ:AVTE
Watchlist
Price: 93.8 USD Market Closed
Market Cap: 77.7m USD

Intrinsic Value

AVTE's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

The intrinsic value of one AVTE stock under the Base Case scenario is 94.94 USD. Compared to the current market price of 93.8 USD, Aerovate Therapeutics Inc is Undervalued by 1%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

AVTE Intrinsic Value
94.94 USD
Undervaluation 1%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Aerovate Therapeutics Inc

Valuation History Unavailable

Historical valuation for AVTE cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%

Fundamental Analysis

Aerovate Therapeutics Inc
NASDAQ:AVTE
US
Biotechnology
Market Cap
77.7m USD
IPO
Jun 30, 2021
US
Biotechnology
Market Cap
77.7m USD
IPO
Jun 30, 2021
Price
$false
EPS
$false
Company Overview
Loading...
Management
Loading...
Contacts
Loading...
AI Assistant
AI Assistant
Ask me anything about Aerovate Therapeutics Inc
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Aerovate Therapeutics Inc

Current Assets 80.1m
Cash & Short-Term Investments 78.6m
Other Current Assets 1.5m
Non-Current Assets 215k
PP&E 215k
Efficiency

Free Cash Flow Analysis
Aerovate Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Aerovate Therapeutics Inc

Revenue
0 USD
Operating Expenses
-74.3m USD
Operating Income
-74.3m USD
Other Expenses
4.7m USD
Net Income
-69.6m USD
Fundamental Scores

AVTE Profitability Score
Profitability Due Diligence

Aerovate Therapeutics Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

23/100
Profitability
Score

Aerovate Therapeutics Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

AVTE Solvency Score
Solvency Due Diligence

Aerovate Therapeutics Inc's solvency score is 78/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
78/100
Solvency
Score

Aerovate Therapeutics Inc's solvency score is 78/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

AVTE Price Targets Summary
Aerovate Therapeutics Inc

Wall Street analysts forecast AVTE stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AVTE is 83.3 USD with a low forecast of 70.7 USD and a high forecast of 110.25 USD.

Lowest
Price Target
70.7 USD
25% Downside
Average
Price Target
83.3 USD
11% Downside
Highest
Price Target
110.25 USD
18% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for AVTE is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

AVTE Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one AVTE stock?

The intrinsic value of one AVTE stock under the Base Case scenario is 94.94 USD.

Is AVTE stock undervalued or overvalued?

Compared to the current market price of 93.8 USD, Aerovate Therapeutics Inc is Undervalued by 1%.

Back to Top